The pleiotropic hormone relaxin-2 plays a pivotal role in the physiology and pathology of the
cardiovascular system. Relaxin-2 exerts relevant regulatory functions in cardiovascular …

Fibrosis refers to the scarring and hardening of tissues, which results from a failed immune
system-coordinated wound healing response to chronic organ injury and which manifests …

Background Clinical consequences of an interplay between dysfunction/injury of different
end‐organs in acute heart failure (AHF) remain unknown. Methods and results In 284 …

Serelaxin, a recombinant form of the naturally occurring peptide hormone relaxin-2, is a
pleiotropic vasodilating hormone that has been studied in patients with acute heart failure. In …

Heart failure remains a leading cause of morbidity and mortality worldwide. Current
treatment for patients with heart failure include drugs targeting G protein‐coupled receptors …

Background: The development and risk potential of hypertension-induced left ventricular
(LV) hypertrophy has been well described in epidemiological studies. Regression of LV …

Serelaxin, a recombinant form of human relaxin-2, is currently regarded as a novel drug for
treatment of acute heart failure. However, whether therapeutic effects of serelaxin are …

Introduction: Heart failure (HF) represents a major health problem because of its high
prevalence, high rates of hospitalizations, and mortality and significant healthcare costs. HF …

Background The insulin/insulin‐like growth factor/relaxin family represents a group of
structurally related but functionally diverse proteins. The family member relaxin‐2 has been …

Aims: To identify a minimum set of efficacy and adverse events for patients with acute heart
failure (AHF) among different stakeholders in clinical trials of traditional Chinese medicine …